The STOP AF First trial demonstrates that cryoballoon catheter ablation is safe and effective for symptomatic paroxysmal atrial fibrillation without the requirement that patients be drug-refractory.
When our researchers surveyed patient and physician perceptions of telemedicine in electrophysiology about a year ago, they had no idea how pertinent their findings would prove in the COVID-19 era.
The studies explore a novel catheter that delivers both pulsed-field and radiofrequency energy, a new method for mapping and ablating scar-related ventricular tachycardia, and high-power/short-duration ablation for atrial fibrillation.
In ablation of scar-related ventricular tachycardia, mapping the heart during activation from multiple directions promises to improve clinical outcomes, suggests the international Physio-VT trial.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
What’s the potential clinical role of the recently reported noninvasive EP-guided cardiac radioablation therapy for ventricular tachycardia? A Cleveland Clinic expert weighs in.